Skip Navigation

Cardiovascular Research 1997 35(3):529-535; doi:10.1016/S0008-6363(97)00165-X
© 1997 by European Society of Cardiology
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow E-letters: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when E-letters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Yap, J
Right arrow Articles by McGregor, C.G.A
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Yap, J
Right arrow Articles by McGregor, C.G.A
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Copyright © 1997, European Society of Cardiology

Immunosuppression prolongs adenoviral mediated transgene expression in cardiac allograft transplantation

J Yapa, T O'Brienb, H.D Tazelaarc and C.G.A McGregora,*

aDepartment of Surgery, Mayo Clinic and Foundation, Rochester, MN 55905, USA
bDepartment of Endocrinology, Mayo Clinic and Foundation, Rochester, MN 55905, USA
cDepartment of Laboratory Medicine and Pathology, Mayo Clinic and Foundation, Rochester, MN 55905, USA

* Corresponding author. Tel.: +1-507-255-6038; fax: +1-507-255-4500.

Background: The immune response to adenoviral vectors used in gene transfer limits the duration of transgene expression and thus poses a potential limitation to their effectiveness for gene therapy. The need for immunosuppression in transplantation may modify this immune response and facilitate prolonged transgene expression. This study hypothesizes that in the setting of heart transplantation, the use of routine immunosuppression will prolong adenoviral-mediated transgene expression. Methods and results: In a model of rat heterotopic abdominal heart transplantation, 350 µl of viral solution (1x109 pfu/ml) was infused into the coronary arteries of donor hearts at the time of procurement. The duration of transgene expression was examined following (a) syngeneic transplantation in non-immunosuppressed animals (group A); (b) syngeneic transplantation in immunosuppressed animals (group B); and (c) allogeneic transplantation in immunosuppressed animals (group C). After transplantation donor hearts were studied at: 1, 4, 8 and 12 weeks. Transgene expression was assessed by histochemical staining of tissue cross sections for β-galactosidase activity. In the non-immunosuppressed syngeneic group (group A), transgene expression had largely disappeared by 4 weeks, whereas in both the immunosuppressed syngeneic (group B) and immunosuppressed allogeneic (group C) animals expression of the reporter gene persisted for the 12 weeks of the study, although the level of expression decreased significantly over time. Conclusions: This study demonstrates that transgene expression using adenoviral vectors is prolonged by immunosuppression in the heart transplantation setting.

KEYWORDS Gene therapy; Heart transplantation; Adenovirus; Immunosuppression


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 J. Thorac. Cardiovasc. Surg.Home page
T. M. Yau, G. Li, R. D. Weisel, A. Reheman, Z.-Q. Jia, D. A. G. Mickle, and R.-K. Li
Vascular endothelial growth factor transgene expression in cell-transplanted hearts
J. Thorac. Cardiovasc. Surg., April 1, 2004; 127(4): 1180 - 1187.
[Abstract] [Full Text] [PDF]

Home page
 J. Biol. Chem.Home page
R. Aikawa, G. S. Huggins, and R. O. Snyder
Cardiomyocyte-specific Gene Expression Following Recombinant Adeno-associated Viral Vector Transduction
J. Biol. Chem., May 17, 2002; 277(21): 18979 - 18985.
[Abstract] [Full Text] [PDF]

Home page
 Eur. J. Cardiothorac. Surg.Home page
J. Yap, C. Pellegrini, T. O'Brien, H. D. Tazelaar, and C. G.A. McGregor
Conditions of vector delivery improve efficiency of adenoviral-mediated gene transfer to the transplanted heart
Eur. J. Cardiothorac. Surg., May 1, 2001; 19(5): 702 - 707.
[Abstract] [Full Text] [PDF]

Home page
 Cardiovasc ResHome page
M. J. Post, R. Laham, F. W. Sellke, and M. Simons
Therapeutic angiogenesis in cardiology using protein formulations
Cardiovasc Res, February 16, 2001; 49(3): 522 - 531.
[Abstract] [Full Text] [PDF]

Home page
 Arterioscler. Thromb. Vasc. Bio.Home page
T. O'Brien
Adenoviral Vectors and Gene Transfer to the Blood Vessel Wall
Arterioscler Thromb Vasc Biol, June 1, 2000; 20(6): 1414 - 1416.
[Full Text] [PDF]

Home page
 J. Thorac. Cardiovasc. Surg.Home page
C. Pellegrini, A. Jeppsson, C. B. Taner, T. O’Brien, V. M. Miller, H. D. Tazelaar, and C. G. A. McGregor
HIGHLY EFFICIENT EX VIVO GENE TRANSFER TO THE TRANSPLANTED HEART BY MEANS OF HYPOTHERMIC PERFUSION WITH A LOW DOSE OF ADENOVIRAL VECTOR
J. Thorac. Cardiovasc. Surg., March 1, 2000; 119(3): 493 - 500.
[Abstract] [Full Text] [PDF]

Home page
 Ann. Thorac. Surg.Home page
M. D. Allen
Myocardial protection: is there a role for gene therapy?
Ann. Thorac. Surg., November 1, 1999; 68(5): 1924 - 1928.
[Abstract] [Full Text] [PDF]

Home page
 Cardiovasc ResHome page
J Yap, T O'Brien, C Pellegrini, D.A Barber, H.D Tazelaar, S.R Severson, V.M Miller, and C.G.A McGregor
Distribution and function of recombinant endothelial nitric oxide synthase in transplanted hearts
Cardiovasc Res, June 1, 1999; 42(3): 720 - 727.
[Abstract] [Full Text] [PDF]

Home page
 J. Thorac. Cardiovasc. Surg.Home page
A. Jeppsson, R. Lee, C. Pellegrini, T. O'Brien, H. D. Tazelaar, and C. G. McGregor
Gene Therapy In Lung Transplantation: Effective Gene Transfer Via The Airways
J. Thorac. Cardiovasc. Surg., March 1, 1998; 115(3): 638 - 643.
[Abstract] [Full Text] [PDF]


Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.